详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations

3| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Naval Med Univ, Dept Histol & Embryol, 800,Xiangyin Rd, Shanghai 200433, Peoples R China [2]Naval Med Univ, Shanghai Key Lab Cell Engn, 800,Xiangyin Rd, Shanghai 200433, Peoples R China [3]Naval Med Univ, Fac Naval Med, Dept Radiat Med, 800,Xiangyin Rd, Shanghai 200433, Peoples R China [4]Naval Med Univ, Fac Med Imaging, Lab Med Imaging, Dept Pathol, 800,Xiangyin Rd, Shanghai 200433, Peoples R China [5]Harbin Med Univ, Dept Histol & Embryol, Harbin 150086, Peoples R China [6]Naval Med Univ, Affiliated Hosp 1, Dept Plast Surg, Shanghai 200433, Peoples R China [7]901th Hosp PLA Jiont Logist Support Force, Hefei 230031, Peoples R China [8]Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Oncol, Shanghai 200336, Peoples R China

出处：

DOI：

ISSN：

关键词： Cancer mutation sequencing CRISPR-Cas9 Gene editing DNA damage repair

摘要：

Developing a strategy to specifically kill cancer cells without inducing obvious damage to normal cells may be of great clinical significance for cancer treatment. In the present study, we developed a new precise personalized strategy named "i-CRISPR" for cancer treatment through adding DNA damage repair inhibitors(i) and inducing cancer cell-specific DNA double strand breaks by CRISPR. Through in vitro and in vivo experiments, we confirmed the efficacy of this strategy in multiple cancer models and revealed the mechanism of cell death. Our strategy might provide a novel concept for precise cancer therapy.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区生化与分子生物学 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区生化与分子生物学 1 区肿瘤学

JCR分区：

出版当年[2020]版：

Q1 ONCOLOGY Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

最新[2023]版：

Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q1 ONCOLOGY

影响因子： 27.7 最新[2023版] 31.3 最新五年平均 27.401 出版当年[2020版] 20.26 出版当年五年平均 15.302 出版前一年[2019版] 41.444 出版后一年[2021版]

第一作者：

第一作者机构： [1]Naval Med Univ, Dept Histol & Embryol, 800,Xiangyin Rd, Shanghai 200433, Peoples R China [2]Naval Med Univ, Shanghai Key Lab Cell Engn, 800,Xiangyin Rd, Shanghai 200433, Peoples R China

共同第一作者：

通讯作者：

通讯机构： [1]Naval Med Univ, Dept Histol & Embryol, 800,Xiangyin Rd, Shanghai 200433, Peoples R China [2]Naval Med Univ, Shanghai Key Lab Cell Engn, 800,Xiangyin Rd, Shanghai 200433, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]靶向bcor基因的crispr/cas9基因编辑系统的建立与基因编辑 [2]CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation [3]应用crispr/cas9技术制备mrgd基因敲除小鼠模型 [4]kcnh6点突变单基因糖尿病家系的小鼠模型构建及表型分析 [5]Unveiling DNA damage repair-based molecular subtypes, tumor microenvironment and pharmacogenomic landscape in gastric cancer [6]The applications and advances of CRISPR-Cas9 in medical research [7]Upregulation of BTF3 affects the proliferation, apoptosis, and cell cycle regulation in hypopharyngeal squamous cell carcinoma [8]In vivo gene therapy potentials of CRISPR-Cas9 [9]CRISPR-Cas9 recognition of enzymatically synthesized base-modified nucleic acids [10]Mup-knockout mice generated through CRISPR/Cas9-mediated deletion for use in urinary protein analysis